Clinical Trial Update: Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer [Phase 3]

View source ↗

Summary

Open-label access protocol update for denosumab in subjects with advanced cancer; results posted after Phase 3 completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases in Men with Hormone-refractory Prostate Cancer
• Bone Metastases in Subjects with Advanced Breast Cancer

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Amgen | Conditions: Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2019-09-09